{"filings":[{"id":650038,"accession_number":"0001493152-26-025170","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-05-26T12:30:22+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports April 2026 unaudited revenue of $325,889, up 57% YoY; launches QHS Practice Access Network","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited April 2026 revenue $325,889, up 57% from $207,538 in April 2025.","Launches QHS Practice Access Network (PAN), independent rep initiative to accelerate Q-Connect adoption.","Plans to present at Planet MicroCap Showcase June 16-18, 2026 to increase investor visibility.","Recurring revenue focus through practice activation and Q-Connect platform expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99224,"accession_number":"0001493152-26-018222","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports 127% YoY ISP revenue growth to $370K in Q1 2026; launches GLP-1 support program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Unaudited Q1 2026 ISP revenue of $370,000, up 127% from $163,000 in Q1 2025.","Launched Q-Connect GLP-1 Support Assessment for anti-obesity medication patients and broader cardiometabolic health.","Growth driven by expanding provider adoption and new product offerings.","Platform expansion into metabolic and behavioral health; CEO cites practical solutions for practices."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":728685.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115109,"accession_number":"0001493152-26-013836","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports fiscal 2025 net income of $457K, revenue up 26% to $2.69M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.69M (+26% YoY); net income $457,417 vs net loss $259,239 in 2024.","Gross margin expanded to 67.3% from 63.7%; gross profit $1.81M vs $1.36M.","Current liabilities reduced to ~$450K from ~$2.4M; cash increased to $636K from $157K.","ISP revenue grew 74% YoY to $1.12M; immunotherapy sales up ~19%.","Recorded ~$1.15M gain on extinguishment of convertible debt; interest expense halved to $237K."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":728685.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115108,"accession_number":"0001493152-26-003526","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports preliminary 2025 revenue up 25% to $2.68M, debt cut to $20k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2,676,074, up 25% YoY; gross profit $1,795,182, up 32% YoY.","Gross margin expanded to ~67% from ~64% in 2024.","Convertible debt reduced from ~$2M to ~$20k; annual interest expense expected to drop >$200k.","Q-Cog pilot generating early reimbursement; expected incremental revenue in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":2691741.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115107,"accession_number":"0001493152-26-003438","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"QHSLab repurchases $470K promissory note with 1.57M shares, extinguishing related-party debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchased and cancelled promissory note held by MedScience; outstanding principal and interest $470,529 as of Dec 31, 2025.","Issued 1,568,432 shares of common stock as consideration; shares issued in private transaction exempt from registration.","CEO Troy Grogan is minority shareholder of MedScience; received no personal distribution from transaction.","Company states repurchase simplifies capital structure and eliminates related-party debt obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115106,"accession_number":"0001493152-26-002496","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab initiates board expansion to add independent directors; convertible debt eliminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Process to add independent board members commenced; interviews and meetings with candidates underway.","Follows elimination of legacy convertible debt, reduced interest expense, and recent funding to limit dilution.","CEO Troy Grogan says independent directors strengthen oversight and support potential uplisting.","Company expects to update shareholders as selection process progresses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115105,"accession_number":"0001493152-26-000527","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports 32% revenue growth to $1.99M, eliminates most convertible debt, cash ~$630k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $1.99M for nine months ended Sep 30, 2025 (+32% YoY); gross margin 66%.","Net operating income before interest $95,738; cash at bank ~$630,000 as of Dec 31, 2025.","Convertible debt reduced from ~$1.4M to $20k; annual interest expense savings >$250k.","Outstanding shares 13,418,899; public float ~2.4M; restricted shares subject to Rule 144.","Management expects net income after interest and depreciation for FY 2025, subject to audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115104,"accession_number":"0001493152-26-000092","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"QHSLab converts $126,548 of note into 421,827 shares; extends remaining $20k to Dec 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $126,548 of principal and accrued interest into 421,827 common shares at $0.30/share.","Remaining $20,000 note balance extended to December 31, 2026; original conversion terms unchanged.","Original note dated May 7, 2021, principal $100,000, 10% interest, matured Dec 31, 2025.","Shares issued in reliance on Section 4(a)(2) and Rule 506; unregistered restricted securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131502,"accession_number":"0001493152-25-029222","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"QHSLab raises $500K in equity, retires $1.4M convertible debt; clean balance sheet entering 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 1,666,663 shares at $0.30/share plus 416,666 warrants exercisable at $0.60 through Dec 2030.","Net proceeds ~$495,000 used for working capital; no broker fees paid.","Retired over $1.4M in 2021-2022 convertible notes (18% default interest, $0.20 conversion) in November 2025.","Annual interest expense cut by more than $200,000; potential dilution from conversion eliminated.","Nine-month 2025 revenue $1.99M (+32% YoY), gross profit $1.32M (66% margin)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131501,"accession_number":"0001493152-25-025892","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab launches Q-Cog cognitive assessment; pilot finds 54% high-risk in 168 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched Q-Cog, a cloud-based digital tool for primary care screening of Mild Cognitive Impairment and dementia.","Initial real-world pilot of 168 patients aged 65+ identified 90 individuals (54%) at high risk, triggering telemedicine referrals.","Tool aligns with CMS Annual Wellness Visit guidelines and supports billing under neurocognitive and behavioral health CPT codes.","CEO Troy Grogan says Q-Cog expands reimbursable digital medicine platform and improves RAF scoring for value-based care.","Company sees new scalable revenue opportunity as over 50% of MCI and up to 80% of dementia cases go undetected in routine visits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131500,"accession_number":"0001493152-25-025495","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab furnishes December 2025 corporate presentation on Form 8-K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["QHSLab, Inc. (USAQ) filed a Form 8-K on December 1, 2025, to furnish its December 2025 Corporate Presentation.","The presentation is attached as Exhibit 99.1 and was made available on December 1, 2025.","The information is furnished under Item 7.01 Regulation FD and is not deemed filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131499,"accession_number":"0001493152-25-024758","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab nine-month revenue $1.99M; retires convertible notes, eliminates dilution overhang","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nine-month 2025 revenue $1.99M, up 32% YoY from $1.51M; gross profit $1.32M.","Unaudited October revenue ~$285k, implying annualized run rate over $3.4M.","Retired two overdue convertible notes (18% interest, $0.20 conversion) removing over $1.4M in liabilities.","DTC float only 2,429,525 shares; structural dilution risk eliminated.","Company expects strong momentum into 2026, focusing on scaling digital-health revenues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131498,"accession_number":"0001493152-25-023990","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["1.01","2.04","7.01","9.01"],"status":"ready","headline":"QHSLab retires $1.4M in convertible notes for $300K; Q3 revenue up 35% to $737K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Repurchased and cancelled $1.4M+ in defaulted convertible notes for $300K cash; conversion rights at $0.20/share eliminated.","Q3 2025 revenue rose 35% YoY to $737,066; gross profit $493,631 (67% margin); operating income $96,251.","Q3 net income of $33,411 vs $49,765 a year ago; YTD net loss of ($99,156) vs $28,350 net income in 2024.","Annualized interest expense reduced by >$200K; cash $158K at Sep 30, 2025; shares outstanding 11,281,527.","CEO cites stronger balance sheet, reduced dilution risk, and focus on growing recurring revenue for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1987931.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148083,"accession_number":"0001641172-25-026187","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab launches Pediatric Health Assessment with multi-location Texas pediatric group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tool integrates behavioral screeners (PSC-17, SDQ) with allergy/asthma metrics (CARAT) and OTC medication use.","CEO Troy Grogan calls launch a 'significant commercial milestone' for QHSLab.","IRB exemption granted for observational study evaluating allergy-behavior link and population health impact.","Product targets back-to-school well-child visits, expanding recurring revenue model.","Strategic positioning for potential pharma, payer, or public health partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148082,"accession_number":"0001641172-25-018099","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab (USAQ) opens first co-branded behavioral health center in Miami with QHS Healthcare","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First QHS Behavioral Healthcare Center (QBHC) opened in Miami on July 8, 2025, in partnership with Global Behavioral Healthcare Group Corp.","Clinic integrates QHSLab's digital screening, AI decision support, and automation with in-person psychiatric and behavioral health services.","Goal is to bridge mental health access gap by connecting patients identified in primary care to specialized care.","QHSLab expects new revenue streams from brand licensing and clinical processes beyond its core digital platform.","Center staffed by local mental health experts under a co-branded arrangement; aligns with QHSLab's mission to expand mental health access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166836,"accession_number":"0001641172-25-013369","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab publishes two peer-reviewed studies validating digital assessment tools in primary care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Journal of Psychosomatic Research: help-seeking behavior in allergic rhinitis reduces negative impact on anxiety and depression.","Q-Scale study in Consultant360 predicts healthcare overutilization using psychosocial factors; enables targeted interventions.","Publications support commercial claims for reimbursement, provider adoption, and revenue growth.","CEO states research validates market position in mental health, preventative screening, and AI-supported care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166835,"accession_number":"0001641172-25-011926","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab issues May 2025 corporate presentation without specific financial updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation covers business and operations; no financial results or guidance included.","Investors should review the filed presentation for any material updates.","Company provides standard forward-looking disclaimer and disclaims obligation to update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166834,"accession_number":"0001641172-25-011175","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab in advanced debt restructuring talks with Catheter Precision to improve balance sheet","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Discussions to restructure OID Notes (previously held by Mercer Street Global Opportunity Fund) held by Catheter Precision.","Proposed terms include higher conversion price, PIK interest option, extended maturity, and removal of default overhang.","Restructuring expected to reduce near-term payments, dilution pressure, and strengthen financial flexibility for growth.","No definitive agreement yet; company expects to finalize and announce in coming weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166833,"accession_number":"0001641172-25-010495","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab Q1 revenue up 32% to $645K; gross margin expands to 66.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $645,419 vs $488,587 in Q1 2024, a 32.1% increase.","Gross margin improved to 66.6% from 58.6% on favorable product mix.","ISP revenue rose 28% to $162,502; Allergy Diagnostics up 11.7% to $264,913.","New clinical study performance obligations contributed $89,100 in revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":645419.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184240,"accession_number":"0001493152-25-008278","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab (USAQ) hires Hayden IR to boost investor visibility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["QHSLab engaged Hayden IR, a national investor relations firm, to raise visibility and strengthen relationships.","CEO Troy Grogan cited significant strides in digital health solutions and provider network expansion.","Hayden IR has over 20 years experience with more than 150 micro- and small-cap companies.","Brett Maas of Hayden IR noted QHSLab's portfolio addresses critical gaps in primary care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184239,"accession_number":"0001493152-25-008228","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.04","9.01"],"status":"ready","headline":"QHSLab receives $1.4M default notice on two convertible notes; expects not to pay by Feb 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Notice of Default from Mercer Street Global Opportunity Fund for two secured promissory notes (August 2021 and July 2022).","Lender demands $1,400,853.77 principal+18% accrued interest; company disputes amount and expects not to meet Feb 27 deadline.","Notes matured Aug 2022 and July 2023, remain unpaid; lender accelerated all amounts due.","Company evaluating financial alternatives; no assurance of resolution; lender may pursue remedies including lien on assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184238,"accession_number":"0001493152-25-007093","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports 98% Q4 revenue surge, first profitable year with net income of $69,188","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $625,981 (+98% YoY); net income $40,838 vs loss $86,627 Q4 2023.","FY 2024 revenue $2.1M (+51% YoY); GAAP net income $69,188 vs loss $468,362 FY 2023.","Gross margin for FY 2024 improved to 63.7% from prior year.","Positive cash flow from ops $247,317; debt repayment $298,531 strengthened balance sheet.","Preliminary unaudited results; full audit expected before SEC 10-K deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":2131926.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184237,"accession_number":"0001493152-25-005807","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab announces co-marketing partnership with Town Total Compounding covering 200+ practices","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership will introduce QHSLab's Integrated Service Program to over 200 primary care practices in Town Total's network.","Collaborates on AI-driven health assessments with customized pharmacy solutions for GLP-1s, HRT, pain management, and more.","Non-dilutive partnership aims to drive organic revenue growth without external financing or equity dilution.","CEO Troy Grogan: combining digital health with customized pharmacy creates scalable, patient-centered care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184236,"accession_number":"0001493152-25-002939","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab furnishes January 2025 Corporate Presentation without specific content","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation filed as Exhibit 99.1, made available on January 21, 2025.","No financial or operational data disclosed in the 8-K text itself.","Presentation may contain material information not summarized in this filing.","Company directs investors to website and social media for updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184235,"accession_number":"0001493152-25-002469","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab to exhibit at Pri-Med South conference Feb 2025, targeting 5,000 primary care professionals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will exhibit at Pri-Med South in Fort Lauderdale, Feb 6-8, 2025.","Conference expected to attract 5,000 primary care professionals.","Marketing materials attached as Exhibit 99.1.","Event targets core audience for QHSLab's products and services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200837,"accession_number":"0001493152-24-050120","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab projects $10M revenue with 250-300 physicians at >65% gross margins","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single provider using full suite can generate $30-50k annual revenue for QHSLab.","Allergy kits ~$100/test; immunotherapy ~$500/patient/year; digital tools $20-40/patient.","Targeting 250-300 physicians to drive over $10M annual revenue at >65% gross margins.","Paid $215k to Mercer debt from cashflow; plans to eliminate debt with new capital.","Expanding sales force by 5 reps in TX, GA, NY; QHS Behavioral Centers by Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200836,"accession_number":"0001493152-24-049905","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab and SDSU receive NSF invitation to submit STTR application for AIR-GUIDDE technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NSF invites QHSLab and South Dakota State University to submit full Phase I STTR application for AIR-GUIDDE drug delivery platform.","Potential NSF funding: Phase I grants up to $305,000; Phase II up to $1.25 million.","AIR-GUIDDE uses CFD modeling to accelerate development and target the $2.6B respiratory drug market.","Project synergizes with QHSLab's existing digital medicine platforms and is non-dilutive to core business.","CEO Troy Grogan says initiative validates company's innovation strategy and is fully aligned with growth plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200835,"accession_number":"0001493152-24-047553","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports Oct sales up 110% to $225k; APA abstracts accepted for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["October 2024 unaudited sales ~$225,000, a 110% increase YoY; annualized run rate $2.7M.","Two research abstracts accepted for presentation at 2025 APA Annual Meeting in Los Angeles.","DMAR study (allergic rhinitis) reached second milestone; participant recruitment exceeded projections.","Company highlights reductions in symptom severity and improved quality of life in mental health studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200834,"accession_number":"0001493152-24-045361","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab Q3 revenue up 62% to $544K, net income $49.8K, gross margin 67.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $544,285 (+62% YoY); gross margin 67.1% (up from 56.3%). Net income $49,765 vs ($82,000) loss in Q3 2023.","ISP (digital health) segment revenue up 126% in Q3 to ~$162K; YTD growth 143% to ~$450K.","Allergy kit sales +48% YoY to ~$220K. Surpassed 100,000 completed digital assessments.","Debt reduction of >$100K from operating cash flow; R&D investment up to $187K YTD.","Secured ~$300K grant for allergic rhinitis digital health research."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1505945.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200833,"accession_number":"0001493152-24-041891","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"QHSLab adds psychiatry advisor Dr. Juan Oms; grants 100k shares in compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Oms will provide strategic advisory services in psychiatry and behavioral health under a 24-month consulting agreement.","As compensation, Dr. Oms receives 100,000 shares of common stock, to be issued within 30 days of October 18, 2024.","Dr. Oms is a board-certified psychiatrist with expertise in substance use disorders, tele-psychiatry, and digital health integration.","Early research data from QHSLab's platform shows significant reductions in PHQ-9 (depression) and GAD-7 (anxiety) scores in primary care patients.","The appointment supports QHSLab's expansion into digital mental health solutions for primary care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200832,"accession_number":"0001493152-24-041717","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports 40% revenue growth, positive cash flow, and strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue increased 40% year-over-year to over $1.5 million in the third quarter of 2024.","Gross profit grew 60% to nearly $1 million, with gross margin exceeding 60%.","Company became cash flow positive and paid over $100,000 against long-term debt from operations.","Engaged two public market veterans to explore strategic opportunities in AI, EVs, robotics, and biotech.","CEO Troy Grogan has taken no compensation for services provided to QHSLab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216835,"accession_number":"0001493152-24-038060","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab secures $297K grant from global consumer health firm for allergic rhinitis digital study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["QHSLab received $297,360 grant from a Global Leader in Consumer Health to advance digital medicine for allergic rhinitis.","Study registered as NCT06603935 on ClinicalTrials.gov; titled 'Harnessing Digital Medicine Tools...'","Research will evaluate QHSLab's AME and ARIS digital tools for primary care allergy management.","Principal Investigator: Marcos Sanchez-Gonzalez, MD, PhD; study aims to improve patient outcomes and reduce costs.","Grant reflects shared commitment to digital health innovation and evidence-based self-care for patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216834,"accession_number":"0001493152-24-036548","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab doubles assessment completions to ~50K year-to-date; two abstracts accepted at ACAAI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Platform processed ~50,000 assessments in 2024 YTD, more than double the same period in 2023.","Two abstracts accepted for presentation at ACAAI conference in Boston; two more submitted for 2025 APA meeting.","R&D focusing on AI-driven digital tools for allergic rhinitis, anxiety, depression, chronic pain.","Preliminary findings from health journeys series show reduced depression, anxiety, pain, allergy scores after few months.","Company continues to integrate digital medicine to reduce non-clinical burden on providers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216833,"accession_number":"0001493152-24-031937","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports strong Q2 2024: revenue +17%, gross margin 62.2%, net loss down 97% to $2.9K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $473,073 (+17% YoY); six-month revenue $961,660 (+27%).","Gross margin improved to 62.2% in Q2 (from 56.0%) and 60.4% YTD (from 54.7%).","Net operating income turned positive $29,967 in Q2 vs $(35,756) loss; six-month operating income $43,571 vs $(156,514) loss.","Net loss reduced to $(2,890) in Q2 from $(106,727); six-month net loss $(21,415) from $(299,282).","Cash from operations improved to $143,961 from $(37,531) outflow in first half."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":961660.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236566,"accession_number":"0001493152-24-023142","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"QHSLab dismisses auditor Accell, engages Astra; prior reports included going concern uncertainty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Accell Audit & Compliance as independent auditor effective June 4, 2024.","Engaged Astra Audit & Advisory LLC as new independent registered public accounting firm for FY 2024.","Accell's 2022 and 2023 audit reports included an explanatory paragraph about going concern uncertainty; no other disagreements or reportable events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236565,"accession_number":"0001493152-24-018806","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab Q1 revenue up 39% to $488K; posts positive operating income of $13.6K vs loss of $120.8K year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $488,587 (+38.6% YoY); Integrated Service Program revenue surged 268% to $127,004.","Gross margin improved to 58.6% from 53.1%; gross profit $286,158.","Operating expenses decreased 11.5% to $272,554; net operating income turned positive to $13,604 from a loss of $120,758.","Allergy Diagnostic Kit sales rose 21% to $237,066; no EPS or net income figures disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":488587.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236564,"accession_number":"0001493152-24-017490","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab appoints Dr. Marcos Sanchez-Gonzalez as VP of Medical and Scientific Affairs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marcos Sanchez-Gonzalez appointed VP of Medical and Scientific Affairs effective May 2, 2024.","He will lead education, communication, and business development strategies for clinicians and providers.","Responsibilities include training, relationship management, post-market clinical evaluation, and conference participation.","CEO Troy Grogan stated Sanchez-Gonzalez will work on a full-time basis to support company growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236563,"accession_number":"0001493152-24-016061","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab reports preliminary Q1 revenue $488,587, up 38% YoY; gross profit $286,157, up 53%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $488,587, up 38% from $352,799 in Q1 2023.","Gross profit $286,157 (59% margin) vs $187,342 (53% margin) a year ago.","CEO Troy Grogan attributes growth to integration of QHSLab software, ISP, and AllergiEnd.","Results are preliminary; full Q1 10-Q to be filed by May 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":488587.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236562,"accession_number":"0001493152-24-015159","cik":856984,"company_name":"QHSLab, Inc.","ticker":"USAQ","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QHSLab furnishes corporate presentation; no specific financial data in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a corporate presentation for meetings with broker-dealers and investors.","Presentation included as Exhibit 99.1; content not detailed in this filing.","No material new financial information disclosed in the 8-K body.","Event is a routine Regulation FD disclosure of investor materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7820000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}